As a leading player in the Indian IVD industry, it is encouraging to know that 70 percent of the treatment decisions are based on lab results. However, the sad part is that even today 70 percent of the instruments used for lab results are imported! And it is all the more ironical that 70 percent Indians have never done any diagnostic tests and are unaware of the disease they have! In a way, these two gaps are interlinked. Most Indians are unable to get diagnostic tests done because they can’t afford it. And they cannot afford it because they are very expensive. And they are very expensive because they are imported!
These are the two gaps that Transasia Bio-Medicals Ltd., India’s number one IVD company, has been striving to bridge. For the last four decades, Transasia has been focusing on innovation to introduce futuristic technologies to meet the needs of the emerging markets.
Our aim has always been to provide affordable, innovative and Make in India solutions. Majority of the labs in India and other emerging countries cannot afford advanced equipment. So, our focus has been on acquiring companies globally that have the necessary expertise in offering the latest technologies, and tailoring them for the target markets. This combined with our commitment to after-sales service and quality has helped us effectively implement a niche differentiation strategy in a somewhat fragmented marketplace.
Our customer first philosophy has made us the preferred choice for all laboratory solutions. With the largest pool of sales, service and application specialists in the industry, we have been successfully able to reach out to the tier I – IV cities and towns.
Customers rely on Transasia not just for our products, but also as an end-to-end solutions provider. Our regular scientific outreach programs are designed to keep our customers abreast with the latest advancements and provide them clinical data that further advocate our technologies. After all, we strongly rely on their expertise for implementing our current plans and identifying means to capitalize on future growth.
Additionally, our latest cloud based system, has helped equip labs with cutting-edge technology to improve lab efficiency and enable better analytic insights.
We are proud of our Make in India products and solutions that consolidate routine and specialized tests on a single platform. Providing enhanced patient care, faster TAT, and seamless workflow form the crux of all our R&D and manufacturing efforts. We are glad to equip over 30,000 laboratories in India and reach out to more than 100 countries worldwide with our Made in India instruments and reagents.
With expertise from our European counterparts, we are developing low cost, easy to use molecular tests for TB, HIV, and hepatitis and expanding our existing portfolio of immunological assays to include the much needed chemiluminescence immunoassay products including a world-class assay to penetrate the fast-growing vitamin D market.
The medium-to-long term growth strategy is to keep the focus on technology; keep launching newer products particularly for the emerging markets and explore opportunities on public-private partnerships within India. We believe that there is a huge potential out there waiting to be tapped. A right product mix with conducive Make in India government policies is the need of the hour!